<DOC>
	<DOCNO>NCT01786135</DOCNO>
	<brief_summary>This phase 1 , open-label , dose-escalation , multicenter study evaluate safety tolerability SGN-CD19A patient relapse refractory B-lineage non-Hodgkin lymphoma ( B-NHL )</brief_summary>
	<brief_title>A Safety Study SGN-CD19A B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pathologically confirm diagnosis mantle cell lymphoma , follicular lymphoma Grade 3 , diffuse large Bcell lymphoma ( DLBCL ) , include transform follicular histology , Burkitt lymphoma , Blineage lymphoblastic lymphoma Relapsed , refractory , progressive disease follow least 1 prior systemic therapy . Patients DLBCL follicular lymphoma Grade 3 must also receive intensive salvage therapy . Eastern Cooperative Oncology Group status 0 1 Measurable disease Allogeneic stem cell transplant ( SCT )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD19</keyword>
	<keyword>B-Lineage Lymphoblastic Lymphoma</keyword>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>B-Cell Lymphoma</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Monomethylauristatin F</keyword>
	<keyword>Follicular Lymphoma Grade 3</keyword>
</DOC>